April 2020 in “The FASEB journal” Poncirin is a promising inhibitor of Janus Kinase 3, potentially better than tofacitinib.
April 2025 in “Turkish Journal of Hematology” Nilotinib may cause gray hair to return to its original color.
November 2025 in “Zenodo (CERN European Organization for Nuclear Research)” Croton tiglium Linn. may promote hair growth but needs careful detoxification due to its toxicity.
3 citations
,
March 2012 in “Arab Journal of Urology” Certain drugs can reduce bladder muscle contractions, potentially helping treat bladder diseases.
65 citations
,
January 2012 in “International Journal of Trichology” N-acetylcysteine may help treat trichotillomania.
August 2018 in “Journal of the American Academy of Dermatology” Tofacitinib is a potential alternative treatment for alopecia totalis, especially in patients with a shorter duration of the condition and more preserved hair follicles, but the overall response rate is low.
September 2024 in “International Journal of Applied Pharmaceutics” A reliable method was developed to measure Finasteride and Tadalafil in rat blood.
1 citations
,
January 2021 in “Dermatologic Therapy” Trichobiolight effectively treats hair loss with 82.5% success.
Ritlecitinib significantly regrows scalp hair in people with alopecia areata.
August 2020 in “Ugeskrift for Læger” A man with severe hair loss regrew all his hair using tofacitinib and stayed healthy for a year.
October 2022 in “Dermatology practical & conceptual” Both treatments help hair regrowth, with PRP being slightly better.
October 2022 in “Dermatologic Therapy” Both treatments for resistant alopecia areata were equally effective.
9 citations
,
October 2025 in “MedComm” PROTACs offer new ways to treat hard-to-target diseases, with promising drugs for cancer in advanced trials.
December 2015 in “OPAL (Open@LaTrobe) (La Trobe University)” QLT0267 stops hair follicle cell growth and movement.
149 citations
,
June 2002 in “Veterinary record/The veterinary record” Trilostane effectively improved symptoms in dogs with a certain adrenal gland disorder.
3 citations
,
June 2018 in “Internal Medicine” Recombinant thrombomodulin can effectively treat severe complications in Cronkhite-Canada syndrome.
January 2011 in “Side effects of drugs annual” Tretinoin gel is safe for sun exposure, but tacalcitol doesn't significantly improve non-segmental vitiligo.
19 citations
,
June 2020 in “BMC Cancer” Trichilemmal carcinoma shares genetic changes with other skin cancers, suggesting similar causes and potential treatments.
Further trials are needed to explore the efficacy of triamcinolone acetonide in dermatology.
October 2025 in “Journal of Mahatma Gandhi University of Medical Sciences and Technology” Amitriptyline can cause temporary hair loss, which stops after discontinuing the drug.
February 2023 in “International Journal of Medical Arts” Trichloroacetic acid is a safe and effective treatment for hair loss in alopecia areata patients.
Baricitinib may reactivate trichilemmal cysts in people with a history of these cysts.
A new mutation in the TRPS1 gene caused Trichorhinophalangeal syndrome in a 17-year-old, highlighting the need for genetic testing.
3 citations
,
January 2017 in “Journal of clinical and diagnostic research” Injecting steroids like Triamcinolone Acetonide for skin treatments can cause Cushing's Syndrome.
October 2021 in “Dermatology Reports” Tofacitinib, a hair regrowth treatment, may worsen acne.
3 citations
,
March 2019 in “Journal of Pigmentary Disorders” Clascoterone and minocycline are effective acne treatments with quick results and fewer side effects.
13 citations
,
January 2018 in “International Journal of Trichology” Intralesional triamcinolone injections can effectively stop frontal fibrosing alopecia with minimal side effects.
1 citations
,
December 1989 in “PubMed” Tretinoin's effectiveness for hair loss is unclear and needs more research.
8 citations
,
July 2020 in “Dermatologic Therapy” Tofacitinib may effectively treat folliculitis decalvans.
September 2022 in “Piretc” The document's conclusion cannot be provided because the document is not accessible or understandable.